drug

pet/spect scan

PET/SPECT Scan
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
PROCEDURE
Pre-approval / investigational in the US
Developed by GlaxoSmithKline
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
PROCEDURE

Indications

Investigational (via trials)
SchizophreniaSchizophrenia

Trials

2
PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations
NCT02983058—Terminated
A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients
NCT00392743—Completed

KOLs & investigators

1
Sander Markx, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
GlaxoSmithKline
company
trial
PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations
NA
trial
A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients
trial
indication
Schizophrenia
indication
Schizophrenia
indication
KOL
Sander Markx, MD
KOL score —
person